De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Egetis Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Egetis Therapeutics heeft een totaal eigen vermogen van SEK401.5M en een totale schuld van SEK108.9M, wat de schuld-eigenvermogensverhouding op 27.1% brengt. De totale activa en totale passiva bedragen respectievelijk SEK646.6M en SEK245.1M.

Belangrijke informatie

27.1%

Verhouding schuld/eigen vermogen

SEK 108.90m

Schuld

Rente dekkingsratio	n/a
Contant	SEK 192.60m
Aandelen	SEK 401.50m
Totaal verplichtingen	SEK 245.10m
Totaal activa	SEK 646.60m

Recente financiële gezondheidsupdates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Dec 21

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Jun 07

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK232.5M ) EGTX } overtreffen de korte termijn passiva ( SEK149.2M ).

Langlopende schulden: De kortetermijnactiva EGTX ( SEK232.5M ) overtreffen de langetermijnschulden ( SEK95.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: EGTX heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van EGTX is de afgelopen 5 jaar gestegen van 0% naar 27.1%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: EGTX heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of EGTX voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Egetis Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Recent updates

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol

Consensus revenue estimates increase by 21%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to kr11.90

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Consensus revenue estimates increase by 13%

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us

Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote

Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data

Chief Executive Officer recently bought kr299k worth of stock

Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020)